• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TPTX

    Turning Point Therapeutics Inc.

    Subscribe to $TPTX
    $TPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0022, a MET/CSF1R/SRC inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in Phase 1/2 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, a preclinical ALK inhibitor for advanced non-small-cell lung cancer. The company was founded in 2013 and is headquartered in San Diego, California.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: tptherapeutics.com

    Peers

    $APLT
    $BTAI
    $CDTX
    $CBAY
    $FATE
    $GTHX
    $HALO
    $MRTX
    $RLAY
    $TGTX
    $EFTR

    Recent Analyst Ratings for Turning Point Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    5/20/2022$58.00Buy
    BofA Securities
    3/1/2022$50.00 → $45.00Hold
    Stifel
    2/10/2022$120.00 → $85.00Overweight
    Wells Fargo
    1/21/2022$115.00 → $105.00Outperform
    Oppenheimer
    12/7/2021Outperform
    Cowen & Co.
    11/10/2021$150.00 → $115.00Outperform
    Oppenheimer
    10/12/2021$178.00 → $162.00Buy
    HC Wainwright & Co.
    10/11/2021Market Outperform → Market Perform
    JMP Securities
    9/30/2021$75.00Hold
    Stifel
    See more ratings

    Turning Point Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Turning Point Therapeutics Inc.

      SC 13G - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/14/22 3:02:35 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Turning Point Therapeutics Inc. (Amendment)

      SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/14/22 2:35:02 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Turning Point Therapeutics Inc. (Amendment)

      SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/9/22 10:01:27 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Turning Point Therapeutics Inc.

      SC 13G - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/4/22 9:24:29 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Turning Point Therapeutics Inc. (Amendment)

      SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/3/22 4:41:27 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Turning Point Therapeutics, Inc. (Amendment)

      SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      6/10/21 11:37:41 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Turning Point Therapeutics, Inc. (Amendment)

      SC 13D/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      4/7/21 4:39:06 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/16/21 3:12:11 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/16/21 12:24:00 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/10/21 11:57:23 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Turning Point Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Nicholson Garry A (tax withholding)

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:43:52 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Machado Patrick (withholding obligation)

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:41:51 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: George Simeon returned $171,278,160 worth of shares to the company (2,253,660 units at $76.00) to cover taxes

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:40:00 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Gallagher Carol Giltner to satisfy tax liability

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:38:34 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Bodem Barbara W.

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:37:04 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Alles Mark J returned $152,000 worth of shares to the company (2,000 units at $76.00), closing all direct ownership in the company to satisfy withholding tax

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:32:55 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Tombesi Paolo returned $2,263,128 worth of shares to the company (29,778 units at $76.00), closing all direct ownership in the company to cover withholding tax

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:31:35 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Sun Brian returned $3,420,000 worth of shares to the company (45,000 units at $76.00), closing all direct ownership in the company (tax liability)

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:29:46 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Sabus Steve M returned $2,786,692 worth of shares to the company (36,667 units at $76.00), closing all direct ownership in the company (withholding obligation)

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:27:59 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Hirmand Mohammad returned $3,137,584 worth of shares to the company (41,284 units at $76.00), closing all direct ownership in the company to cover withholding tax

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:26:11 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Turning Point Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Turning Point Therapeutics with a new price target

      BofA Securities initiated coverage of Turning Point Therapeutics with a rating of Buy and set a new price target of $58.00

      5/20/22 7:27:32 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on Turning Point with a new price target

      Stifel reiterated coverage of Turning Point with a rating of Hold and set a new price target of $45.00 from $50.00 previously

      3/1/22 11:13:37 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo reiterated coverage on Turning Point with a new price target

      Wells Fargo reiterated coverage of Turning Point with a rating of Overweight and set a new price target of $85.00 from $120.00 previously

      2/10/22 7:06:48 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer reiterated coverage on Turning Point with a new price target

      Oppenheimer reiterated coverage of Turning Point with a rating of Outperform and set a new price target of $105.00 from $115.00 previously

      1/21/22 8:38:45 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen & Co. initiated coverage on Turning Point

      Cowen & Co. initiated coverage of Turning Point with a rating of Outperform

      12/7/21 4:56:58 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer reiterated coverage on Turning Point with a new price target

      Oppenheimer reiterated coverage of Turning Point with a rating of Outperform and set a new price target of $115.00 from $150.00 previously

      11/10/21 7:43:30 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Turning Point with a new price target

      HC Wainwright & Co. reiterated coverage of Turning Point with a rating of Buy and set a new price target of $162.00 from $178.00 previously

      10/12/21 6:35:47 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point downgraded by JMP Securities

      JMP Securities downgraded Turning Point from Market Outperform to Market Perform

      10/11/21 6:47:47 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Turning Point with a new price target

      Stifel initiated coverage of Turning Point with a rating of Hold and set a new price target of $75.00

      9/30/21 4:54:50 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Turning Point with a new price target

      HC Wainwright & Co. reiterated coverage of Turning Point with a rating of Buy and set a new price target of $186.00 from $190.00 previously

      4/6/21 6:07:01 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Turning Point Therapeutics Inc. SEC Filings

    See more
    • SEC Form 15-12G filed by Turning Point Therapeutics Inc.

      15-12G - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/29/22 4:30:18 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Turning Point Therapeutics Inc.

      EFFECT - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/23/22 12:15:10 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Turning Point Therapeutics Inc.

      S-8 POS - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/17/22 9:02:17 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Turning Point Therapeutics Inc.

      S-8 POS - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/17/22 9:02:21 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Turning Point Therapeutics Inc.

      S-8 POS - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/17/22 9:02:25 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Turning Point Therapeutics Inc.

      S-8 POS - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/17/22 9:02:13 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Turning Point Therapeutics Inc.

      25-NSE - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      8/17/22 9:01:03 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Turning Point Therapeutics Inc.

      POS AM - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/17/22 9:01:03 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits

      8-K - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/17/22 8:44:51 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 14D9/A filed by Turning Point Therapeutics Inc. (Amendment)

      SC 14D9/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      8/16/22 7:10:11 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Turning Point Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axonis Therapeutics Announces $115 Million Series A Financing

      -- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

      10/30/24 6:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies

      - venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

      8/1/24 8:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Global Precision Medicine Market Size Demonstrates Consistent Growth with a CAGR of 11.12%, with North America Taking a Leading Role

      New York, United States, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Precision medicine is a new approach to treating and preventing disease that considers each individual's genetic, environmental, and lifestyle differences. Giving the proper treatment to the right patient at the right time is the goal of precision medicine. According to Straits Research, "North America is dominating the market with the highest revenue and is expected to reach USD 97.32 billion in 2030, growing at a CAGR of 9.7% during the forecast period," Download Free Sample Report PDF @ https://straitsresearch.com/report/precision-medicine-market/request-sample Key Drivers DNA sequencing technology has undergone

      11/8/23 9:50:00 AM ET
      $BMY
      $ILMN
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics

      Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) ("Turning Point") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), and the receipt of merger control clearance from the Federal Cartel Office of Germany ("FCO"), in connection with the previously announced offer (the "Offer") to acquire all outstanding shares of common stock of Turning Point at a price of $76.00 per share in an all-cash transaction for total consideration of approximately $4.1 billion. The expiration of the HSR Act waiting period occurred at 11:59 p.m. Eastern Time on August 15, 2022, and the FCO clear

      8/16/22 6:59:00 AM ET
      $BMY
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates

      Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinibInitiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer (NSCLC) Plan to provide detailed update for TRIDENT-1 registrational ROS1-positive NSCLC population and additional data for NTRK-positive solid tumor population, as well as SHIELD-1 Phase 1 data at medical conference in 2H 2022On track to submit data to FDA to support elzovantinib recommended Phase 2 dose (RP2D) and for initiation of potentially registrational Phase 2 SHIELD-1 Study

      8/8/22 4:17:00 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC

      SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced receipt of positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed within the second quarter. The feedback focused on the planned patient follow-up within the ROS1+ advanced non-small cell lung cancer (NSCLC) patient cohorts of the ongoing TRIDENT-1 registrational study of repotrectinib, the company's lead drug candidate, which is a potential best-in-class ROS1 tyrosine kinase inhibitor that has received

      7/27/22 4:05:00 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Reports Second Quarter Financial Results for 2022

      Reports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY; or 5% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.66 and Non-GAAP EPS of $1.93; Includes Net Impact of ($0.14) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Charges and Licensing Income Delivers Robust Revenue Growth of 11% from In-Line Products and New Product Portfolio; or 16% When Adjusted for Foreign Exchange Expands Oncology Franchise with New Indications for Opdivo and Planned Acquisition of Precision Oncology Company, Turning Point Therapeutics Strengthens Cell Therapy Franchise with Broadest Label for Breyanzi in Relapsed or Refractory Large B-cell Lymph

      7/27/22 6:59:00 AM ET
      $BMY
      $IMTX
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Bristol Myers Squibb Announces Extension of Turning Point Tender Offer

      Bristol Myers Squibb (NYSE:BMY) today has announced that Rhumba Merger Sub Inc. ("Offeror"), a wholly owned subsidiary of Bristol Myers Squibb, has extended the expiration date of its offer (the "Offer") to acquire (the "Acquisition") all of the outstanding shares of common stock, par value $0.0001 per share ("Common Stock"), of Turning Point Therapeutics, Inc. (NASDAQ:TPTX), ("Turning Point") at a price of $76.00 per share, in cash, without interest, subject to any applicable withholding of taxes, pursuant to the terms of the Agreement and Plan of Merger, dated as of June 2, 2022, among Bristol Myers Squibb, Offeror and Turning Point (the "Merger Agreement"). The Acquisition is expected to

      7/19/22 6:59:00 AM ET
      $BMY
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies

      HOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, and The University of Texas MD Anderson Cancer Center today announced a strategic research and development alliance to expand the evaluation of two of Turning Point's investigational small molecules focusing on precision medicine targets well known in oncology. The initial focus of the alliance will be Turning Point's lead drug candidate, repotrectinib, a next-generation kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer and advan

      6/24/22 9:00:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Turning Point Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Bristol Myers Squibb Reports Second Quarter Financial Results for 2022

      Reports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY; or 5% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.66 and Non-GAAP EPS of $1.93; Includes Net Impact of ($0.14) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Charges and Licensing Income Delivers Robust Revenue Growth of 11% from In-Line Products and New Product Portfolio; or 16% When Adjusted for Foreign Exchange Expands Oncology Franchise with New Indications for Opdivo and Planned Acquisition of Precision Oncology Company, Turning Point Therapeutics Strengthens Cell Therapy Franchise with Broadest Label for Breyanzi in Relapsed or Refractory Large B-cell Lymph

      7/27/22 6:59:00 AM ET
      $BMY
      $IMTX
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines

      Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three Additional ADC Programs SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, announced today that it has entered into an exclusive license agreement with LaNova Medicines Limited (LaNova) to develop and commercialize LM-302, a novel antibody drug conjugate (ADC) targeting Claudin18.2, in the U.S. and rest of the world, excluding Greater Chi

      5/5/22 9:00:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study

      In a total of 71 TKI-naïve patients, confirmed objective response rate (cORR) of 79% (95% CI: 68, 88)In the TKI-naïve population with approximately 10 months of follow-up, initial estimated durability of response and progression free survival of 85% and 82% at 12-month landmarks, respectivelyIn TKI-pretreated patients, cORR of 42% in those treated with 1 TKI and platinum-based chemotherapy (EXP-2), cORR of 28% in those treated with two TKIs (EXP-3), and cORR of 36% in those treated with 1 TKI (EXP-4) In TKI-pretreated patients with an identified ROS1 G2032R solvent front mutation, cORR of 59%Pre-NDA meeting anticipated this quarter to discuss potential NDA in ROS1-positive NSCLC Conference C

      4/12/22 4:46:10 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates

      Updated Preliminary Clinical Data Presented for Lead Drug Candidate Repotrectinib and Elzovantinib at the AACR-NCI-EORTC ConferenceMultiple FDA Interactions Anticipated in Q4 2021 and 1H 2022 for Repotrectinib and ElzovantinibCash, Cash Equivalents, and Marketable Securities of $1.0 Billion Expected to Fund Current Operations into 2024 SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results for the third quarter ended September 30, 2021 and provided operational updates. "We are encouraged by the progress made across

      11/9/21 4:01:00 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics to Host Third Quarter 2021 Conference Call

      SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it will report third quarter financial results following the close of U.S. financial markets on November 9. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results and provide operational updates. President and CEO Athena Countouriotis, M.D., will host the call, which will include a question and answer session. The update will be accessible via audio webcast through the "Investors" section of www.tptherapeutics.com or by dialing (877) 388

      11/2/21 4:01:00 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates

      Repotrectinib Demonstrates Clinical Activity Across Multiple ROS1+ TKI-Pretreated NSCLC Cohorts, with Confirmed Objective Response Rates of 30-39 Percent in TRIDENT-1 StudyRepotrectinib Demonstrates Confirmed Objective Response Rate of 53 Percent in ROS1+ TKI-Pretreated NSCLC Patients with G2032R Solvent Front MutationElzovantinib (TPX-0022) Demonstrates Confirmed Objective Response Rates of 36 and 33 Percent, Respectively, in MET TKI-Naïve NSCLC and Gastric/Gastroesophageal Junction (GEJ) Cancer Patients Harboring Genetic Alterations in MET in SHIELD-1 Study Repotrectinib Early Clinical Data in NTRK+ TKI-Naïve and TKI-Pretreated Solid Tumors to be Presented in Plenary Session on October 8 a

      10/7/21 7:00:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Announces Additional Details for Three Data Presentations at the 2021 AACR-NCI-EORTC Conference

      SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced additional details for its data presentations, including a late-breaking plenary presentation, from ongoing clinical trials for lead drug candidate, repotrectinib, and TPX-0022, a novel MET/SRC/CSF1R inhibitor. These data will be presented at the Virtual International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment o

      9/30/21 4:30:00 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates

      Phase 1/2 TRIDENT-1 Enrollment Reaches Approximately 300 Patients, Including More than 50 in the ROS1-Positive TKI-naïve NSCLC Cohort (EXP-1)TPX-0022 Granted Fast Track Designation in MET Amplified Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction (GEJ) Adenocarcinoma after Prior Chemotherapy SHIELD-1 Phase 1 Expansion Cohorts Initiated TRIDENT-1, SHIELD-1 and CARE Studies Accepted for Clinical Data Presentations at Medical Conferences in OctoberFour Discovery Research Programs Ongoing with First 2 Development Candidates Targeted in 2H 2022; Goal to Achieve At Least 1 New IND Every Year Beginning in 2023Cash, Cash Equivalents, and Marketable Securities of $1.1 Billion Expect

      8/9/21 4:02:00 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics to Host Second Quarter 2021 Conference Call

      SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report second quarter financial results following the close of U.S. financial markets on August 9. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results and provide operational updates. President and CEO Athena Countouriotis, M.D., will host the call, which will include a question and answer session. The update will be accessible via audio webcast through the "Investors" section of www.tptherapeutics.com or by dialing (877) 388-2118 (in the United St

      7/28/21 4:15:00 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Turning Point Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer

      SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022. Prior to Turning Point, Mr. Sabus spent 15 years in roles with increasing levels of sales responsibility at Astellas Pharma, most recently serving as the Head of Oncology leading a group of over 300 team members. In this role he provided executive leadership to scale the company's $3 billion U.S. oncology franchise by launching and growing new products. His achievements include su

      5/16/22 8:30:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel

      SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior Vice President and General Counsel, effective as of April 11, 2022. Mr. Sun currently serves as Senior Vice President and General Counsel at Sorrento Therapeutics, Inc, a Nasdaq-listed company, where he leads the legal function and team. Previously, he worked at Prometheus Laboratories and Hologic and served as outside general counsel to early-stage biotechnology companies. Earlier in his career, Mr

      3/29/22 9:00:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syneos Health Appoints Two New Independent Directors

      MORRISVILLE, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors. "We are excited to welcome Barbara and Alfonso to the Syneos Health Board," said John Dineen, Chair of the Syneos Health Board of Directors. "Barbara's deep financial expertise combined with Alfonso's expansive industry knowledge and international experience bring important perspectives to an already strong Board. These two leaders will enhance the composition of our Board and support continued successful overs

      1/18/22 6:16:16 AM ET
      $CTS
      $SYNH
      $TPTX
      Electrical Products
      Technology
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Turning Point Therapeutics Announces Appointment of Adam Levy as Senior Vice President of Investor Relations

      SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Adam Levy, Ph.D., MBA, as senior vice president of Investor Relations and Corporate Communications, effective today. Dr. Levy brings more than 20 years of experience to Turning Point, including a strong background in investor relations, corporate strategy and communications. Prior to joining Turning Point, he served as executive vice president of Corporate Development and Investor Relations at Ziopharm Oncology. Previously, Dr. Levy served as executive directo

      11/8/21 4:01:00 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer

      SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr. Tombesi brings 30 years of global financial and accounting experience to Turning Point from multiple prior financial leadership roles within biotech and pharmaceutical companies, most recently serving as CFO of Epizyme, Inc. "Paolo brings very valuable global financial experience to our growing team, particularly in supporting commercial organizations and product launches," said Athena Countouriotis, M.D., pre

      6/29/21 9:00:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Names Former Celgene Chairman and CEO, Mark Alles, to Chair Its Board of Directors

      SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its board of directors. Garry Nicholson, who is currently the interim chair, will remain on the board. Mr. Alles is an accomplished biopharmaceutical executive who led successful global oncology-focused organizations over his more than three-decade career, which includes driving growth and innovation during 15 years at Celgene until its $74-billion acquisition by Bristol Myers Squibb in 2019. President and

      5/25/21 9:00:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer

      SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Kumar Srinivasan, Ph.D., MBA, as executive vice president and chief business officer, effective June 1. Dr. Srinivasan has over 20 years of experience in pharmaceutical and biotechnology companies, most recently as vice president and global head of business development for the BioPharmaceutical business unit of AstraZeneca. "As we advance now four clinical stage drug candidates and enhance our pipeline for the future, Kumar brings deep expertise to help guide o

      5/17/21 9:00:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care